Equities research analysts expect Apricus Biosciences (NASDAQ:APRI) to post earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Apricus Biosciences’ earnings. Apricus Biosciences reported earnings per share of ($0.15) in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The firm is expected to announce its next earnings results on Wednesday, August 1st.
On average, analysts expect that Apricus Biosciences will report full-year earnings of ($0.40) per share for the current financial year. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Apricus Biosciences.
Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, May 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04).
A number of equities research analysts have issued reports on the company. HC Wainwright lowered Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Friday, February 16th. Zacks Investment Research lowered Apricus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. Finally, ValuEngine raised Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
An institutional investor recently bought a new position in Apricus Biosciences stock. Healthcare Value Capital LLC bought a new position in shares of Apricus Biosciences (NASDAQ:APRI) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences makes up approximately 0.6% of Healthcare Value Capital LLC’s portfolio, making the stock its 8th largest position. Healthcare Value Capital LLC owned 0.66% of Apricus Biosciences at the end of the most recent reporting period. Institutional investors own 12.97% of the company’s stock.
APRI stock opened at $0.28 on Friday. Apricus Biosciences has a 1 year low of $0.25 and a 1 year high of $3.34.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.
Get a free copy of the Zacks research report on Apricus Biosciences (APRI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.